32 Health Systems Spending $5B on Cancer Care

Why It Matters

These unprecedented expenditures will broaden patient access to advanced therapies, cement oncology as a core revenue engine for health systems, and reshape the competitive landscape of U.S. cancer care.

Key Takeaways

• 32 systems commit >$5 billion to expand oncology infrastructure through 2028
• Projects include new hospitals, outpatient centers, and specialized labs, many over $100 million
• Financing blends philanthropy, federal grants, and system capital, diversifying revenue streams
• Focus on survivorship, precision diagnostics, and immunotherapy drives care model shift
• Decentralized sites bring advanced treatment to rural and underserved populations

Pulse Analysis

The $5 billion infusion marks the largest coordinated capital wave in U.S. oncology in a decade, signaling that health systems view cancer care as a strategic growth pillar rather than a cost center. From a $22.7 million renovation in Michigan to OHSU’s $650 million Vista Pavilion, projects are designed to accommodate the expanding survivorship phase, integrate precision diagnostics, and support high‑value therapies such as CAR‑T and proton beam radiation. By 2028, many of these facilities will double infusion capacity, add dedicated oncology pharmacies, and embed research capabilities, positioning hospitals to capture both clinical and research revenue streams.

Funding sources are as varied as the projects themselves. Philanthropic gifts—like the $2 billion Knight endowment to OHSU and a $1.68 billion joint‑venture commitment at Dana‑Farber—co‑exist with federal allocations for rural PET/CT scanners and state‑approved bonds for proton‑therapy centers. This blended financing mitigates risk for health systems while allowing rapid deployment of technology that would otherwise be delayed by budget constraints. The reliance on private capital also underscores the competitive race to attract top oncology talent and clinical trial enrollment, which are increasingly tied to institutional prestige and payer negotiations.

For patients, the geographic dispersion of these new sites promises faster access to cutting‑edge treatments, especially in underserved regions where travel barriers have historically limited care. Decentralized outpatient hubs and specialized women’s‑cancer centers aim to embed survivorship services—nutrition, mental health, and genetic counseling—into the treatment pathway, improving outcomes and reducing long‑term costs. As the oncology market continues to grow, health systems that successfully integrate these capabilities will likely see stronger payer contracts, higher patient volumes, and a reinforced position in the evolving landscape of value‑based cancer care.